SaifM. (2014). MM-398 Achieves Primary Endpoint of Overall Survival in Phase III Study in Patients with Gemcitabine Refractory Metastatic Pancreatic Cancer. JOP. Journal of the Pancreas, 15(3), 278-279. https://doi.org/10.6092/1590-8577/2507